Schizophrenia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Striatal CB1R may contribute to the pathophysiology of WM deficits in male patients and have implications for drug development in schizophrenia.
|
31801965 |
2019 |
Schizophrenia
|
0.600 |
Biomarker
|
disease |
BEFREE |
The most well established finding is the down-regulation of cannabinoid CB1 receptors (CB1R) after chronic and recent cannabis exposure, but it remains uncertain whether this effect is present in cannabis users with schizophrenia.
|
30635160 |
2019 |
Schizophrenia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Therefore, the endocannabinoid system could represent a therapeutic target for schizophrenia as a regulator of glutamate and GABA release via the CB1 receptor (CB1R).
|
31202911 |
2019 |
Schizophrenia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
<b>Background:</b> Several studies have revealed significant associations between single nucleotide polymorphisms (SNPs) in the cannabinoid receptor 1 (<i>CNR1</i>) gene and a broad spectrum of psychiatric disorders such as major depressive disorder (MDD), attention deficit hyperactivity disorder (ADHD), and schizophrenia.
|
29963071 |
2018 |
Schizophrenia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
To gain insight into this factor, we assessed the postnatal developmental trajectory of CB1R expression in the methylazoxymethanol (MAM) model of schizophrenia.
|
29705007 |
2018 |
Schizophrenia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The hippocampi of schizophrenia-like brains that were treated with the cannabinoid receptor-1 inverse antagonist AM251 expressed H3K9ac at the level observed in normal brains.
|
28300292 |
2018 |
Schizophrenia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Indeed, in several brain regions implicated in the putative neural circuitry of SZ (e.g., hippocampus, frontal cortex, cerebellum), cannabinoid receptor type 1 (CB1Rs) and glutamate N-methyl-D-aspartate receptors (NMDARs) have direct and indirect interactions.
|
29247465 |
2018 |
Schizophrenia
|
0.600 |
Biomarker
|
disease |
BEFREE |
The present review surveys what is currently known about the interactions of CB1Rs with dopamine, serotonin, and glutamate systems, because all three of those neurotransmitters are well-established in the pathophysiology of schizophrenia and psychosis.
|
29385930 |
2018 |
Schizophrenia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Papers were retrieved from PubMed and ISI Web of Knowledge using the search term schizophrenia in combination with CNR1 or CB1 or cannabinoid receptor.
|
28099629 |
2017 |
Schizophrenia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The results point towards the hypothesis that increased CB1R levels could be a confounding effect of antipsychotic medication in schizophrenia that is circumveneted by high fat feeding.
|
28619471 |
2017 |
Schizophrenia
|
0.600 |
Biomarker
|
disease |
BEFREE |
The involvement of CB1 receptor ligands in the schizophrenia has already been revealed and confirmed.
|
28138895 |
2017 |
Schizophrenia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Overall, our findings suggest a selective dysregulation of ECS in psychosis, and highlight the evaluation of CNR1 DNA methylation levels in PBMCs as a potential biomarker for schizophrenia.
|
28108228 |
2017 |
Schizophrenia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Cannabinoid receptor 1 (CNR1) gene polymorphisms have been associated with central and peripheral effects of cannabis and schizophrenia pathophysiology.
|
26071625 |
2015 |
Schizophrenia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In this study, although the result indicates that CNR1 and CNR2 variations are unlikely to influence schizophrenia susceptibility in a Korean population, the findings would provide meaningful information for further genetic studies.
|
25014618 |
2014 |
Schizophrenia
|
0.600 |
Biomarker
|
disease |
BEFREE |
In either case, greater CB1R receptor availability may contribute to the increased susceptibility of schizophrenia subjects to the deleterious effects of cannabis use.
|
25107849 |
2014 |
Schizophrenia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In the present study, we investigated three polymorphisms (rs1049353, rs806368, and rs4707436) in the cannabinoid type 1 receptor gene (CNR1) and weight gain in Korean patients with schizophrenia receiving olanzapine treatment.
|
21695734 |
2013 |
Schizophrenia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We previously reported that marijuana misuse in conjunction with specific cannabinoid receptor 1 (CNR1) genetic variants (rs12720071-G-allele carriers) contributed to white-matter (WM) brain volume deficits in schizophrenia patients.
|
22850347 |
2013 |
Schizophrenia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These results provide evidence that the prevalence of MetS is associated with the CNR1 gene in patients with SCZ during long-term treatment with antipsychotic treatment.
|
23422373 |
2013 |
Schizophrenia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Seven out of the 32 tSNPs within PPARA (rs4253765, rs4263776, rs6007662, rs1800206, rs4253763, rs6008197 and rs4253655) and 3 out of 12 tSNPs within CNR1 (rs1049353, rs7766029 and rs806366) were nominally associated with SZ (uncorrected p<0.05).
|
22920733 |
2013 |
Schizophrenia
|
0.600 |
Biomarker
|
disease |
BEFREE |
The specific binding of [(3)H]MePPEP to CB(1) receptors was 20% higher in patients with schizophrenia than in controls.
|
22910406 |
2012 |
Schizophrenia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The findings that reduced GAD(67) mRNA expression can induce lower CB1R mRNA expression support the hypothesis that lower cortical levels of CB1Rs in schizophrenia may partially compensate for deficient GAD(67)-mediated GABA synthesis by reducing endogenous cannabinoid suppression of GABA release.
|
22036037 |
2012 |
Schizophrenia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Twenty tagSNPs spanning the CNR1 gene were analyzed in schizophrenia patients of European ancestry (n=191; 74 with TD).
|
21266946 |
2012 |
Schizophrenia
|
0.600 |
Biomarker
|
disease |
BEFREE |
No study to-date has systematically investigated the impact of CNR1 on quantitative phenotypic features in schizophrenia and inter-relationships with marijuana misuse.
|
21420833 |
2011 |
Schizophrenia
|
0.600 |
Biomarker
|
disease |
CTD_human |
Recently, an (AAT)n triplet repeat polymorphism within the cannabinoid receptor gene CNR1 has been found to be associated with both schizophrenia and substance dependence, and to modulate the P300 potential.
|
21513772 |
2011 |
Schizophrenia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Recently, an (AAT)n triplet repeat polymorphism within the cannabinoid receptor gene CNR1 has been found to be associated with both schizophrenia and substance dependence, and to modulate the P300 potential.
|
21513772 |
2011 |